|
|
Zerit (Stavudine, d4T)
| Brand Name: |
Zerit |
| Generic Name: |
Stavudine, d4T |
| Adult Single Dose: |
Patients weighing at least 133 lbs (60 kg): one 40-mg capsule (every 12 hours)
Patients weighing less than 133 lbs (60 kg): one 30-mg capsule (every 12 hours) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- An Overview of Zerit (Stavudine, d4T) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Stavudine (Zerit) (August 23, 2009)
To read PDF, click here
From AIDS InfoNet
- Zerit (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Patient Information About Zerit (Stavudine, d4T) (PDF) (November 2008)
From Bristol-Myers Squibb Company
- Zerit (Stavudine, d4T) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- d4T (Stavudine, Zerit) (October 26, 2006)
From AIDS Treatment Data Network
- Zerit (Stavudine) (May 2005)
[Archived Article]
To read PDF, click here
From The Center for AIDS
- Drug Interactions: Stavudine (August 2004)
[Archived Article]
From Project Inform
News
- FDA Approval of Three Generic Stavudine Formulations (December 30, 2008)
From U.S. Food and Drug Administration
- Drop d4T From First-Line Therapy, WHO Advises Low-Income Countries – If You Can Afford To (August 8, 2006)
In aidsmap.com
- FDA Tentatively Approves Generic Pediatric d4T for PEPFAR (December 22, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Efavirenz, Stavudine Demand May Soon Exceed Supply in Developing World (March 4, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- South African Generic Drug Maker to Produce Country's First Generic Antiretroviral Drug (August 7, 2003)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- It's Time to Face the Zerit Problem (March 2003)
[Archived Article]
Nelson Vergel urges Bristol-Myers Squibb to do more to minimize the lipoatrophy effects of d4T (stavudine, Zerit), and recommends it no longer be used as first-line treatment in the meantime.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- FDA Approves Zerit Once Daily, Extended Release Formulation (January 10, 2003)
[Archived Article]
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Zerit XR Enters the Home Stretch (December 2002)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- d4T and Lactic Acidosis With Neuromuscular Weakness: FDA Warning (March 8, 2002)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Changes in Zerit Product Labeling Reflect Potential Safety Concerns (February 2002)
[Archived Article]
From U.S. Food and Drug Administration
- FDA/Bristol Myers Squibb Issues Caution for HIV Combination Therapy With Zerit and Videx in Pregnant Women (January 5, 2001)
[Archived Article]
From U.S. Food and Drug Administration
- ddI, d4T and Hydroxyurea Side Effect Warning! (April 2000)
[Archived Article]
In Project Inform Perspective, from Project Inform
- Initial Therapy With d4T or 3TC Appears to Confer Survival Benefit (April 1998)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
Research
- d4T Toxicity Risk 7-Fold Higher When Started With TB Treatment (June 18, 2009)
From aidsmap.com
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
- Abacavir Is Not Associated With the Metabolic Changes Seen in Patients Treated With Stavudine (February 24, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Both Tenofovir and Stavudine Well Tolerated in HCV-Coinfected Patients (July 12, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Micronutrient Supplement Can Improve d4T-, ddI-Related Neuropathy, Study Says (March/April 2004)
[Archived Article]
In Positively Aware, from Test Positive Aware Network
- Predicting Lipoatrophy After Treatment Initiation (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
[Archived Article]
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases
- A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- For Potency Tenofovir Equals d4T but Tenofovir Beats d4T With Less Frequent and Common Side Effects (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Forty-Eight Week Data From FTC-d4T Comparison in Treatment-Naive Patients (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- More Results Reported on Study 903: Tenofovir + 3TC + Efavirenz Vs. d4T + 3TC + Efavirenz (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Trizivir Causes Lowest Triglycerides Rise in Comparison With Combivir + Nelfinavir or d4T (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Lack of Interaction Between Stavudine Extended-Release Formulation and Tenofovir Disoproxil Fumarate (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efficacy and Safety of Tenofovir DF Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients: 96-Week Preliminary Interim Results (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- New Questions About an Old Combination -- ddI + d4T (January 2003)
[Archived Article]
To read PDF, click here
In Project Inform Perspective, from Project Inform
- Approval of Zerit XR, a New Formulation That Allows Once-a-Day Dosing (December 31, 2002)
[Archived Article]
From U.S. Food and Drug Administration
- Research From the 42nd ICAAC: A Nucleoside (FTC) and a Nucleotide (Tenofovir) Outdo d4T (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Comparison of the Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy After 48 Weeks of Treatment (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Genotypic and Phenotypic Characterization of Virologic Failure Through 48 Weeks Among Treatment-Naive Patients Taking Tenofovir DF or Stavudine in Combination With Lamivudine and Efavirenz (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Intracellular Metabolism of AZT Leads to the Production of Significant Levels of d4T Triphosphate in HIV Infected Patients (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Successful Switch From Stavudine to Once-Daily Tenofovir Based Regimen in Patients With Fully Suppressed HIV (October 26, 2002)
[Archived Article]
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- The Case Against Zerit (October 2002)
[Archived Article]
Research increasingly points to NRTIs -- particularly d4T -- as a likely culprit in metabolic disorders.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- FTC Superiority Over d4T in Phase III Trial (September/October 2002)
[Archived Article]
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy: 48-Week Interim Results (July 12, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- d4T (stavudine, Zerit): New Once-a-Day Formulation (March 2002)
[Archived Article]
In Project Inform Perspective, from Project Inform
- Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Switching Stavudine or Zidovudine to Abacavir for HIV Lipoatrophy: A Randomized, Controlled, Open-Label, Multicentre, 24-Week Study (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Diverse Effects of NRTI-Associated Mutations on Resistance to Abacavir, Stavudine and Zidovudine in the ZORRO Trial (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Pancreatitis: An Emerging Complication of HCV Treatment in HIV Co-Infected Patients Treated With Didanosine/Stavudine Containing Regimens (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Long-Term Follow-Up of Antiretroviral-Naive HIV-Infected Patients Treated with d4T and ddI (QD) and Nevirapine (BID or QD) in the VIRGO Study (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Abacavir/Combivir/Nelfinavir, or Lamivudine/Stavudine/NFV (GSK Protocol ESS40002) (October 26, 2001)
[Archived Article]
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Efficacy and Safety of Switch to 3TC 300 mg QD vs. Continued 3TC 150 mg BID in Subjects with Virologic Suppression on Stable 3TC/d4T/PI Therapy (COLA4005): Final 24-Week Results (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Phosphorylation of Zidovudine, Stavudine, and Abacavir in Peripheral Blood Mononuclear Cells in Treatment-Naive and Treatment-Experienced Patients (February 5, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Lactic Acidosis and Hepatic Steatosis Associated With Use of Stavudine: Report of Four Cases (August 1, 2000)
[Archived Article]
In Annals of Internal Medicine
- Two Studies Shed Light on Development of d4T Resistance (July 13, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Studies Suggest Nevirapine Can Be Dosed Either Once or Twice Daily; Effective at Both High and Low Viral Loads (July 11, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Stavudine for the Treatment of HIV Neurocognitive Impairment (June 29 and July 2, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
- A Randomized Double-Blind Study of d4T + ddI versus ZDV + ddI as Initial Treatment in Subjects with CD4 Count <= 500 cells/mm3 (February 4, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Study in HIV Positive Women of Quadruple Therapy: Nelfinavir, Saquinavir, Stavudine, and Lamivudine (February 4, 1998)
[Archived Article]
From Seattle Treatment Education Project
- Therapy with d4T plus 3TC Produces Sustained Undetectable Levels of Plasma HIV RNA in Patients Treated with Reverse Transcriptase Inhibitors for 10 Years (February 4, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Combination Therapy With AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients With Less Than 200 CD4/mm3 (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- d4T+3TC Versus AZT+3TC: Shattering the Synergy Story (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The START Trials (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Should AZT and d4T Be Used Together? (February 2, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Role of d4T in Initial Combination Regimens (February 2, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- d4T and 3TC Combination Studies Confirm the Effect of the Combination (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- ddI + d4T Combination Therapy Proves Effective (January 1997)
[Archived Article]
In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- d4T Plus ddI Antiviral Results (February 1996)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
|
Advertisement
|
E-Mail
Glossary
Share